IMforte shows lurbinectedin plus atezolizumab maintenance extends PFS and OS in extensive-stage SCLC, with manageable cytopenias and key patient-selection guidance.

Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune ...

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

Gut microbiota may shape liver metastasis in small cell lung cancer and influence treatment response. Read more.

Lung cancer remains one of the leading causes of cancer deaths around the world. Among the different types of lung cancer, ...

Professor Chao Zhang's team at Zhujiang Hospital, Southern Medical University, has developed a novel DNA nanomachine-based drug delivery and release strategy aimed at overcoming chemoresistance in ...

Phase 2a trial of atebimetinib + mGnP in first-line pancreatic cancer patients, well above the standard of care benchmark from GnP of 35% overall survival; On track for expanded pancreatic cancer ...

The NICE committee concluded that it needed additional data on various survival endpoints and further cost-effectiveness analyses.

In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

Oncology projects currently take up about 40% of Pfizer’s overall R&D budget. | After steering positive key pivotal readouts for a trio of Novartis’ blockbusters, Jeff Legos is now tasked with ...

A study published today by the DARU Journal of Pharmaceutical Sciences reports that combining cannabidiol (CBD) with the anti ...